CA3279458C - Produits médicinaux et procédés d'atténuation du syndrome de libération de cytokine associé à l'immunothérapie anticancéreuse - Google Patents

Produits médicinaux et procédés d'atténuation du syndrome de libération de cytokine associé à l'immunothérapie anticancéreuse

Info

Publication number
CA3279458C
CA3279458C CA3279458A CA3279458A CA3279458C CA 3279458 C CA3279458 C CA 3279458C CA 3279458 A CA3279458 A CA 3279458A CA 3279458 A CA3279458 A CA 3279458A CA 3279458 C CA3279458 C CA 3279458C
Authority
CA
Canada
Prior art keywords
map kinase
kinase inhibitor
cells
cell
crs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3279458A
Other languages
English (en)
Other versions
CA3279458A1 (fr
Inventor
Brendan BUCKLEY
Liam TREMBLE
Original Assignee
Poolbeg Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poolbeg Pharma UK Ltd filed Critical Poolbeg Pharma UK Ltd
Publication of CA3279458A1 publication Critical patent/CA3279458A1/fr
Application granted granted Critical
Publication of CA3279458C publication Critical patent/CA3279458C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne un inhibiteur de p38 MAP kinase destiné à être utilisé dans la prévention ou la réduction de la gravité de signes ou de symptômes du syndrome de libération de cytokine associé à l'immunothérapie anticancéreuse ("CRS") chez un patient humain, l'inhibiteur de p38 MAPK étant administré avant l'apparition de CRS. L'invention concerne également des procédés, des produits et des utilisations associés.
CA3279458A 2023-01-13 2024-01-12 Produits médicinaux et procédés d'atténuation du syndrome de libération de cytokine associé à l'immunothérapie anticancéreuse Active CA3279458C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2300510.1 2023-01-13
GB2300512.7 2023-01-13
GB2316713.3 2023-11-01
GB2316715.8 2023-11-01
GB2316714.1 2023-11-01

Publications (2)

Publication Number Publication Date
CA3279458A1 CA3279458A1 (fr) 2024-07-18
CA3279458C true CA3279458C (fr) 2026-04-28

Family

ID=

Similar Documents

Publication Publication Date Title
US9539245B2 (en) Combination of immunotherapies with activators of Tie-2
US20220401474A1 (en) Hdac6-activated macrophages, compositions, and uses thereof
EP1993584B1 (fr) Inhibiteurs de l'activité de CXCR4 pour son utilisation dans le traitement des maladies oculaires
US20180071376A1 (en) Tolerogenic nanoparticles for treating diabetes mellitus
CN114246864B (zh) Csf1r激酶抑制剂及其用途
JP2020059703A (ja) 免疫除去療法
US20240287195A1 (en) Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
US20220313626A1 (en) Small molecule inhibitors for treating cancer in a subject having tumors with high interstitial pressure
AU2024208037B2 (en) Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome
JP2021505172A (ja) 造血幹細胞及び前駆細胞を動員させるための投薬レジメン
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CN113018438A (zh) Cxcr2抑制剂在制备治疗鼻咽癌的药物中的用途
CN108078987A (zh) 阿苯达唑在制备治疗胶质母细胞瘤的药物中的用途
JP2022050478A (ja) Ｉｌｃ２細胞に関連する疾患を処置する方法
US20240245682A1 (en) Alpha-v-beta-8 integrin inhibitors and uses thereof
US12365651B2 (en) Use of pirfenidone and derivatives for modulation of B lymphocyte activity and organ protection from acute tissue damage
HK1259026A1 (zh) 用於治疗癌症的抗趋除剂的局部递送
WO2023055786A1 (fr) Formulations d'hydrogel, vaccins et leurs méthodes d'utilisation
US20220401481A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
RU2831407C1 (ru) Способ лечения больных первичной диффузной В-клеточной крупноклеточной лимфомой ЦНС
US20230414565A1 (en) Compositions and methods for treating hematological malignancies
JP6993812B2 (ja) 細胞傷害活性を向上させたリンパ球の培養方法及び該方法で得られた細胞傷害活性を向上させたリンパ球を含む細胞免疫治療剤
WO2022101676A1 (fr) Matériaux et procédés de traitement du cancer
BR122025023560A2 (pt) Uso de composição farmacêutica compreendendo um glicocorticoide no tratamento de uma doença mediada por linfócito
JP2021059495A (ja) アルベンダゾール含有単球分化誘導剤